BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/17/2016 8:44:00 AM | Browse: 1730 | Download: 2393
 |
Received |
|
2016-04-29 15:31 |
|
Peer-Review Started |
|
2016-05-04 13:54 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-07-05 10:37 |
|
Revised |
|
2016-07-06 10:48 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-07-21 17:20 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2016-08-01 15:30 |
|
Articles in Press |
|
2016-08-01 15:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-08-09 10:02 |
|
Publish the Manuscript Online |
|
2016-08-17 08:44 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jian-Hong Zhong, Xue-Ke Du, Bang-De Xiang and Le-Qun Li |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guangxi Science and Technology Development Projects |
14124003-4 |
| Guangxi University of Science and Technology Research Projects |
KY2015LX056 |
| the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province |
Z2015621 |
| the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province |
Z2015601 |
| the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province |
GZZC15-34 |
| the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province |
Z2014241 |
| the Innovation Project of Guangxi Graduate Education |
YCBZ2015030 |
|
| Corresponding Author |
Le-Qun Li, MD, Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd #71, Nanning 530021, Guangxi Zhuang Autonomous Region, China. xitongpingjia@163.com |
| Key Words |
Adjuvant; Hepatocellular carcinoma; Tumor recurrence; Sorafenib |
| Core Tip |
Sorafenib is effective for advanced hepato-cellular carcinoma (HCC). However, its positive role as adjuvant therapy for HCC after surgery or transarterial chemoembolization is controversy. |
| Publish Date |
2016-08-17 08:44 |
| Citation |
Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i23/957.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i23.957 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
